Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

被引:6
作者
Liang, Yan [1 ,2 ]
Zhang, Purong [1 ]
Li, Feng [1 ,2 ]
Lai, Houyun [1 ,2 ]
Qi, Tingting [1 ]
Wang, Yixin [1 ]
机构
[1] Univ Elect Sci & Technol, Sichuan Canc Hosp, Canc Hosp, Chengdu, Peoples R China
[2] Univ Elect Sci & Technol, Sch Med, Chengdu, Peoples R China
关键词
breast cancer; T-DM1; T-DXd; SG; ADC; GROWTH-FACTOR RECEPTOR; TRASTUZUMAB EMTANSINE T-DM1; PHASE-III ASCENT; SACITUZUMAB GOVITECAN; OPEN-LABEL; PHYSICIANS CHOICE; SINGLE-ARM; DERUXTECAN; SURVIVAL; RESISTANCE;
D O I
10.3389/fphar.2023.1332539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer continues to have a high incidence rate among female malignancies. Despite significant advancements in treatment modalities, the heterogeneous nature of breast cancer and its resistance to various therapeutic approaches pose considerable challenges. Antibody-drug conjugates (ADCs) effectively merge the specificity of antibodies with the cytotoxicity of chemotherapeutic agents, offering a novel strategy for precision treatment of breast cancer. Notably, trastuzumab emtansine (T-DM1) has provided a new therapeutic option for HER2-positive breast cancer patients globally, especially those resistant to conventional treatments. The development of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) has further broadened the applicability of ADCs in breast cancer therapy, presenting new hopes for patients with low HER2 expression and triple-negative breast cancer. However, the application of ADCs presents certain challenges. For instance, their treatment may lead to adverse reactions such as interstitial lung disease, thrombocytopenia, and diarrhea. Moreover, prolonged treatment could result in ADCs resistance, complicating the therapeutic process. Economically, the high costs of ADCs might hinder their accessibility in low-income regions. This article reviews the structure, mechanism of action, and clinical trials of commercially available ADCs for breast cancer treatment, with a focus on the clinical trials of the three drugs, aiming to provide insights for clinical applications and future research.
引用
收藏
页数:26
相关论文
共 148 条
[91]   Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer [J].
Modi, Shanu ;
Saura, Cristina ;
Yamashita, Toshinari ;
Park, Yeon Hee ;
Kim, Sung-Bae ;
Tamura, Kenji ;
Andre, Fabrice ;
Iwata, Hiroji ;
Ito, Yoshinori ;
Tsurutani, Junji ;
Sohn, Joohyuk ;
Denduluri, Neelima ;
Perrin, Christophe ;
Aogi, Kenjiro ;
Tokunaga, Eriko ;
Im, Seock-Ah ;
Lee, Keun Seok ;
Hurvitz, Sara A. ;
Cortes, Javier ;
Lee, Caleb ;
Chen, Shuquan ;
Zhang, Lin ;
Shahidi, Javad ;
Yver, Antoine ;
Krop, Ian .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) :610-621
[92]   Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial [J].
Montemurro, F. ;
Delaloge, S. ;
Barrios, C. H. ;
Wuerstlein, R. ;
Anton, A. ;
Brain, E. ;
Hatschek, T. ;
Kelly, C. M. ;
Pena-Murillo, C. ;
Yilmaz, M. ;
Donica, M. ;
Ellis, P. .
ANNALS OF ONCOLOGY, 2020, 31 (10) :1350-1358
[93]   Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial [J].
Mosele, Fernanda ;
Deluche, Elise ;
Lusque, Amelie ;
Le Bescond, Loic ;
Filleron, Thomas ;
Pradat, Yoann ;
Ducoulombier, Agnes ;
Pistilli, Barbara ;
Bachelot, Thomas ;
Viret, Frederic ;
Levy, Christelle ;
Signolle, Nicolas ;
Alfaro, Alexia ;
Tran, Diep T. N. ;
Garberis, Ingrid Judith ;
Talbot, Hugues ;
Christodoulidis, Stergios ;
Vakalopoulou, Maria ;
Droin, Nathalie ;
Stourm, Aurelie ;
Kobayashi, Maki ;
Kakegawa, Tomoya ;
Lacroix, Ludovic ;
Saulnier, Patrick ;
Job, Bastien ;
Deloger, Marc ;
Jimenez, Marta ;
Mahier, Celine ;
Baris, Vianney ;
Laplante, Pierre ;
Kannouche, Patricia ;
Marty, Virginie ;
Lacroix-Triki, Magali ;
Dieras, Veronique ;
Andre, Fabrice .
NATURE MEDICINE, 2023, 29 (08) :2110-+
[94]   Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade [J].
Mueller, Philipp ;
Kreuzaler, Matthias ;
Khan, Tarik ;
Thommen, Daniela S. ;
Martin, Kea ;
Glatz, Katharina ;
Savic, Spasenija ;
Harbeck, Nadia ;
Nitz, Ulrike ;
Gluz, Oleg ;
von Bergwelt-Baildon, Michael ;
Kreipe, Hans ;
Reddy, Sai ;
Christgen, Matthias ;
Zippelius, Alfred .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (315)
[95]   The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy [J].
Nakada, Takashi ;
Sugihara, Kiyoshi ;
Jikoh, Takahiro ;
Abe, Yuki ;
Agatsuma, Toshinori .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (03) :173-185
[96]   Prognostic and predictive biomarkers in breast cancer: Past, present and future [J].
Nicolini, Andrea ;
Ferrari, Paola ;
Duffy, Michael J. .
SEMINARS IN CANCER BIOLOGY, 2018, 52 :56-73
[97]   Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC) [J].
O'Shaughnessy, J. ;
Brufsky, A. ;
Rugo, H. S. ;
Tolaney, S. M. ;
Diab, S. ;
Punie, K. ;
Sardesai, S. ;
Hamilton, E. ;
Loirat, D. ;
Traina, T. A. ;
Leon-Ferre, R. ;
Hurvitz, S. A. ;
Kalinsky, K. ;
Bardia, A. ;
Henry, S. ;
Mayer, I. ;
Hong, Q. ;
Phan, S. ;
Cortes, J. .
ANNALS OF ONCOLOGY, 2021, 32 :S473-S474
[98]   Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer [J].
O'Shaughnessy, Joyce ;
Brufsky, Adam ;
Rugo, Hope S. ;
Tolaney, Sara M. ;
Punie, Kevin ;
Sardesai, Sagar ;
Hamilton, Erika ;
Loirat, Delphine ;
Traina, Tiffany ;
Leon-Ferre, Roberto ;
Hurvitz, Sara A. ;
Kalinsky, Kevin ;
Bardia, Aditya ;
Henry, Stephanie ;
Mayer, Ingrid ;
Zhu, Yanni ;
Phan, See ;
Cortes, Javier .
BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) :127-139
[99]   Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+tucatinib/placebo in patients with residual HER2-positive invasive breast cancer [J].
O'Sullivan, Ciara C. ;
Ballman, Karla, V ;
McCall, Linda ;
Kommalapati, Anuhya ;
Zemla, Tyler ;
Weiss, Anna ;
Mitchell, Melissa ;
Blinder, Victoria ;
Tung, Nadine M. ;
Irvin, William J. ;
Lee, Myounghee ;
Goetz, Matthew P. ;
Symmans, William Fraser ;
Borges, Virginia F. ;
Krop, Ian ;
Carey, Lisa A. ;
Partridge, Ann H. .
FUTURE ONCOLOGY, 2021, 17 (34) :4665-4676
[100]   A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study) [J].
Patel, Tejal A. ;
Ensor, Joe E. ;
Creamer, Sarah L. ;
Boone, Toniva ;
Rodriguez, Angel A. ;
Niravath, Poly A. ;
Darcourt, Jorge G. ;
Meisel, Jane L. ;
Li, Xiaoxian ;
Zhao, Jing ;
Kuhn, John G. ;
Rosato, Roberto R. ;
Qian, Wei ;
Belcheva, Anna ;
Schwartz, Mary R. ;
Kaklamani, Virginia G. ;
Chang, Jenny C. .
BREAST CANCER RESEARCH, 2019, 21 (01)